U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Central Nervous System Non-Hodgkin Lymphoma

MedGen UID:
1641189
•Concept ID:
C4687631
•
Neoplastic Process

Definition

The reemergence of central nervous system non-Hodgkin lymphoma after a period of remission. [from NCI]

Professional guidelines

PubMed

Treatment Options for Recurrent Primary CNS Lymphoma.
Kaulen LD, Baehring JM
Curr Treat Options Oncol 2022 Nov;23(11):1548-1565. Epub 2022 Oct 7 doi: 10.1007/s11864-022-01016-5. PMID: 36205806
Evidence-based expert consensus on the management of primary central nervous system lymphoma in China.
Chen T, Liu Y, Wang Y, Chang Q, Wu J, Wang Z, Geng D, Yu JT, Li Y, Li XQ, Chen H, Zhuang D, Li J, Wang B, Jiang T, Lyu L, Song Y, Qiu X, Li W, Lin S, Zhang X, Lu D, Lei J, Chen Y, Mao Y
J Hematol Oncol 2022 Sep 29;15(1):136. doi: 10.1186/s13045-022-01356-7. PMID: 36176002Free PMC Article
Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma.
Moleti ML, Testi AM, Foà R
Br J Haematol 2020 Jun;189(5):826-843. Epub 2020 Mar 6 doi: 10.1111/bjh.16461. PMID: 32141616

Recent clinical studies

Etiology

Prevention and management of secondary central nervous system lymphoma.
Bobillo S, Khwaja J, Ferreri AJM, Cwynarski K
Haematologica 2023 Mar 1;108(3):673-689. doi: 10.3324/haematol.2022.281457. PMID: 36384246Free PMC Article
Treatment Options for Recurrent Primary CNS Lymphoma.
Kaulen LD, Baehring JM
Curr Treat Options Oncol 2022 Nov;23(11):1548-1565. Epub 2022 Oct 7 doi: 10.1007/s11864-022-01016-5. PMID: 36205806
Blastoid Mantle Cell Lymphoma.
Jain P, Wang M
Hematol Oncol Clin North Am 2020 Oct;34(5):941-956. Epub 2020 Aug 5 doi: 10.1016/j.hoc.2020.06.009. PMID: 32861288
Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma.
Moleti ML, Testi AM, Foà R
Br J Haematol 2020 Jun;189(5):826-843. Epub 2020 Mar 6 doi: 10.1111/bjh.16461. PMID: 32141616
Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
Ollila TA, Olszewski AJ
Curr Treat Options Oncol 2018 Jun 21;19(8):38. doi: 10.1007/s11864-018-0555-8. PMID: 29931605Free PMC Article

Diagnosis

Primary central nervous system lymphoma.
Schaff LR, Grommes C
Blood 2022 Sep 1;140(9):971-979. doi: 10.1182/blood.2020008377. PMID: 34699590Free PMC Article
Blastoid Mantle Cell Lymphoma.
Jain P, Wang M
Hematol Oncol Clin North Am 2020 Oct;34(5):941-956. Epub 2020 Aug 5 doi: 10.1016/j.hoc.2020.06.009. PMID: 32861288
Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma.
Moleti ML, Testi AM, Foà R
Br J Haematol 2020 Jun;189(5):826-843. Epub 2020 Mar 6 doi: 10.1111/bjh.16461. PMID: 32141616
Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
Ollila TA, Olszewski AJ
Curr Treat Options Oncol 2018 Jun 21;19(8):38. doi: 10.1007/s11864-018-0555-8. PMID: 29931605Free PMC Article
Primary CNS Lymphoma.
Grommes C, DeAngelis LM
J Clin Oncol 2017 Jul 20;35(21):2410-2418. Epub 2017 Jun 22 doi: 10.1200/JCO.2017.72.7602. PMID: 28640701Free PMC Article

Therapy

Prevention and management of secondary central nervous system lymphoma.
Bobillo S, Khwaja J, Ferreri AJM, Cwynarski K
Haematologica 2023 Mar 1;108(3):673-689. doi: 10.3324/haematol.2022.281457. PMID: 36384246Free PMC Article
Primary central nervous system lymphoma.
Schaff LR, Grommes C
Blood 2022 Sep 1;140(9):971-979. doi: 10.1182/blood.2020008377. PMID: 34699590Free PMC Article
Blastoid Mantle Cell Lymphoma.
Jain P, Wang M
Hematol Oncol Clin North Am 2020 Oct;34(5):941-956. Epub 2020 Aug 5 doi: 10.1016/j.hoc.2020.06.009. PMID: 32861288
Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma.
Moleti ML, Testi AM, Foà R
Br J Haematol 2020 Jun;189(5):826-843. Epub 2020 Mar 6 doi: 10.1111/bjh.16461. PMID: 32141616
Primary CNS Lymphoma.
Grommes C, DeAngelis LM
J Clin Oncol 2017 Jul 20;35(21):2410-2418. Epub 2017 Jun 22 doi: 10.1200/JCO.2017.72.7602. PMID: 28640701Free PMC Article

Prognosis

Primary central nervous system lymphoma.
Schaff LR, Grommes C
Blood 2022 Sep 1;140(9):971-979. doi: 10.1182/blood.2020008377. PMID: 34699590Free PMC Article
Blastoid Mantle Cell Lymphoma.
Jain P, Wang M
Hematol Oncol Clin North Am 2020 Oct;34(5):941-956. Epub 2020 Aug 5 doi: 10.1016/j.hoc.2020.06.009. PMID: 32861288
Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma.
Moleti ML, Testi AM, Foà R
Br J Haematol 2020 Jun;189(5):826-843. Epub 2020 Mar 6 doi: 10.1111/bjh.16461. PMID: 32141616
Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
Ollila TA, Olszewski AJ
Curr Treat Options Oncol 2018 Jun 21;19(8):38. doi: 10.1007/s11864-018-0555-8. PMID: 29931605Free PMC Article
Primary CNS Lymphoma.
Grommes C, DeAngelis LM
J Clin Oncol 2017 Jul 20;35(21):2410-2418. Epub 2017 Jun 22 doi: 10.1200/JCO.2017.72.7602. PMID: 28640701Free PMC Article

Clinical prediction guides

Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse.
Rusconi C, Cheah CY, Eyre TA, Tucker D, Klener P, Giné E, Crucitti L, Muzi C, Iadecola S, Infante G, Bernard S, Auer RL, Pagani C, Duglosz-Danecka M, Mocikova H, van Meerten T, Cencini E, Marin-Niebla A, Williams ME, Angelillo P, Nicoli P, Arcari A, Morello L, Mannina D, Vitagliano O, Sartori R, Chiappella A, Sciarra R, Stefani PM, Dreyling M, Seymour JF, Visco C
Blood 2022 Oct 27;140(17):1907-1916. doi: 10.1182/blood.2022015560. PMID: 35789260
Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.
Scordo M, Wang TP, Ahn KW, Chen Y, Ahmed S, Awan FT, Beitinjaneh A, Chen A, Chow VA, Dholaria B, Epperla N, Farooq U, Ghosh N, Grover N, Hamad N, Hildebrandt GC, Holmberg L, Hong S, Inwards DJ, Jimenez-Jimenez A, Karmali R, Kenkre VP, Khimani F, Klyuchnikov E, Krem MM, Munshi PN, Nieto Y, Prestidge T, Ramakrishnan Geethakumari P, Rezvani AR, Riedell PA, Seo S, Shah NN, Solh M, Yared JA, Kharfan-Dabaja MA, Herrera A, Hamadani M, Sauter CS
JAMA Oncol 2021 Jul 1;7(7):993-1003. doi: 10.1001/jamaoncol.2021.1074. PMID: 33956047Free PMC Article
Central Nervous System Lymphomas.
Grommes C
Continuum (Minneap Minn) 2020 Dec;26(6):1476-1494. doi: 10.1212/CON.0000000000000936. PMID: 33273169
Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†.
Ghesquieres H, Chevrier M, Laadhari M, Chinot O, Choquet S, Moluçon-Chabrot C, Beauchesne P, Gressin R, Morschhauser F, Schmitt A, Gyan E, Hoang-Xuan K, Nicolas-Virelizier E, Cassoux N, Touitou V, Le Garff-Tavernier M, Savignoni A, Turbiez I, Soumelis V, Houillier C, Soussain C
Ann Oncol 2019 Apr 1;30(4):621-628. doi: 10.1093/annonc/mdz032. PMID: 30698644
Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
Ollila TA, Olszewski AJ
Curr Treat Options Oncol 2018 Jun 21;19(8):38. doi: 10.1007/s11864-018-0555-8. PMID: 29931605Free PMC Article

Recent systematic reviews

Central nervous system (CNS) prophylaxis in antiCD20-CHOP treated DLBCL at intermediate to high risk for CNS relapse: A systematic review and meta-analysis.
Ho G, Tan C, de Mel S, Poon L, Chan EHL, Lee J, Liu X, Chng WJ, Chee YL, Soon YY, Jeyasekharan AD
Crit Rev Oncol Hematol 2021 Nov;167:103507. Epub 2021 Oct 14 doi: 10.1016/j.critrevonc.2021.103507. PMID: 34656744
Novel agents for primary central nervous system lymphoma: evidence and perspectives.
Illerhaus G, Schorb E, Kasenda B
Blood 2018 Aug 16;132(7):681-688. Epub 2018 Jul 9 doi: 10.1182/blood-2018-01-791558. PMID: 29986908
Influence of Rituximab on Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma and Role of Prophylaxis--A Systematic Review of Prospective Studies.
Ghose A, Elias HK, Guha G, Yellu M, Kundu R, Latif T
Clin Lymphoma Myeloma Leuk 2015 Aug;15(8):451-7. Epub 2015 Mar 5 doi: 10.1016/j.clml.2015.02.026. PMID: 25816933
Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era.
Fletcher CD, Kahl BS
Leuk Lymphoma 2014 Oct;55(10):2228-40. Epub 2014 Feb 24 doi: 10.3109/10428194.2013.869326. PMID: 24286262
Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis.
Zhang J, Chen B, Xu X
Leuk Lymphoma 2014 Mar;55(3):509-14. Epub 2013 Jul 29 doi: 10.3109/10428194.2013.811239. PMID: 23741977

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...